xm:钟大放
xb:男
zc:研究员
xl:博士
dh:
cz:
dzyj:dfzhong@simm.ac.cn
grzy:
zjlb:研究员；****；新药；
zw:中科院上海药物所研究员、博士生导师、研究组长、药物代谢研究中心主任
txdz:上海市浦东新区张江高科技园区海科路501号
grjj:钟大放博士，上海药物研究所药物代谢研究中心主任，课题组长。主要从事药物的生物转化和体内处置研究，生物样品分析方法和技术开发，创新药物申报所需的吸收、分布、代谢和排泄试验，以及植物药的代谢生物活化及毒性研究。曾主持7项国家自然科学基金项目，1996年获国家****科学基金。他的研究工作导致在亚洲人群中发现新的突变等位基因CYP2C9*13，并且将其与氯诺昔康和甲苯磺丁脲经CYP2C9代谢清除多态性相关联。他的研究工作阐明了天然产物鱼腥草素、绿原酸和雷公藤内酯醇生物活化机制。钟博士已经发表SCI论文210余篇（他引2000余次），国内期刊论文220余篇（他引2300余次），出版药物代谢专著和译著5部。指导毕业博士生48名，硕士生90余名。近年来，他的团队开展了240余项新药临床前ADME试验，约占中国申报临床试验新药总数的30%。其中，160余项获得中国临床试验批件，多项获得美国或澳大利亚临床试验许可。还与临床医院合作，参与新药临床代谢和药动学试验100余项。在参与的药物代谢研究项目中，已经有13种在中国批准上市（艾瑞昔布、埃克替尼、阿利沙坦酯、海姆泊芬、吗啉硝唑、阿帕替尼、奈诺沙星、吡咯替尼、呋喹替尼、可利霉素、氟马替尼、瑞马唑仑、阿美替尼）。此外，他的团队还开展了400多项制剂生物等效性试验。钟博士在中国制定生物分析和药物代谢法规性指导原则方面发挥了关键作用，是中国药典2015年版《生物样品定量分析方法验证指导原则》和《药物制剂人体生物利用度和生物等效性试验指导原则》的起草人。钟博士目前担任国家药典委员会委员，中国药物代谢学会副主任委员，以及多种学术期刊的编委。
yjfx:1. 建设符合国际标准的药物代谢研究平台
2. 生物样品定量分析方法研究
3. 药物代谢产物追踪和结构鉴定
4. 创新药物代谢和药动学评价
5. 药物代谢酶和药物转运体相关的体内药物相互作用机制研究
6. 放射性同位素方法用于药物代谢研究
7. 抗体药物药动学研究
dblz: 1.Li XL, Guo ZT, Wang YD, Chen XY, Liu J, Zhong DF*. Potential role of organic anion transporting polypeptide 1B1 in the selective hepatic uptake of hematoporphyrin monomethyl ethyl ether isomers. Acta Pharmacologica Sinica, 2015, 36: 268-2802.Zhu YT, Deng P, Zhong DF*. Derivatization methods for LC–MS analysis of endogenous compounds. Bioanalysis, 2015, 7:2557-25813.Liu C, Chen ZQ, Zhong K, Li L, Zhu WL, Chen XY, Zhong DF*. Human liver cytochrome P450 enzymes and microsomal thiol methyltransferase are involved in the stereoselective formation and methylation of the pharmacologically active metabolite of clopidogrel. Drug Metabolism and Disposition, 2015, 43: 1632-16414.Zhu YT, Li L, Deng P, Chen XY, Zhong DF*. Characterization of TPN729 metabolites in humans usingultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 117: 217–2265.Zhang YF, Dai XJ, Yang Y, Chen XY, Wang T, Tang YB, Tsai CY, Chang LW, Chang YT, Zhong DF*. Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers. Drug Design, Development and Therapy, 2016, 10: 357-3706.Zhu YT, Li L, Zhang G, Wan H, Yang CY, Diao XX, Chen XY, Zhang LS, Zhong DF*. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Journal of Chromatography B, 2016, 1033-1034: 117-1277.Jiang JF, Pang XH, Li L, Dai XJ, Diao XX, Chen XY, Zhong DF*, Wang YW, Chen YW. Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide. Drug Design, Development and Therapy, 2016, 10: 2181-21918.Yu MM, Gao ZW, Dai XJ, Gong H, Zhang LS, Chen XY, Zhong DF*, Sy SKB*. Population pharmacokibetic and covariate analysis of apatinib, an oral tyrosine kinase inhibitor, in healthy volunteers and patients with solid tumors. Clinical Pharmacokinetics, 2017, 56: 65-769.Zhang YF, Chen XY, Tang YB, Lu YM, Guo LX, Zhong DF*. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study. Drug Design, Development and Therapy, 2017, 11: 2109-211910.Jiang JF, Chen XY, Zhong DF*. Arylacetamide deacetylase is involved in vicagrel bioactivation in humans. Frontiers in Pharmacology, 2017, 8: 846(1-8)11.Xu Y, Zhang YF, Chen XY, Zhong DF*. CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats. Acta Pharmacologica Sinica, 2018, 39: 1386-139212.Zhang D, Yang CY, Chen XY, Li XL*, Zhong DF*. A bridging immunogenicity assay for monoclonal antibody: case study with SHR-1222. Bioanalysis, 2018, 10: 1115-111713.Liu XY, Zhang YF, Chen Q, Zhan Y, Wang QR, Hu CY, Yu C, Guo ZT, Chen XY, Zhong DF*. Pharmacokinetic drug interactions of apatinib with rifampin and itraconazole. Journal of Clinical Pharmacology, 2018, 58: 347-35614.Liu C, Lu YM, Sun HB, Yang J, Liu YQ, Lai XJ, Gong YC, Liu XF, Li YG, Zhang YF, Chen XY, Zhong DF*. Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149: 394-40215.Jiang JF, Chen XY, Zhong DF*. Predominant contribution of carboxylesterase 1 and 2 in hydrolysis of anordrin in human. Xenobiotica, 2018, 48: 533-54016.Liu C, Zhang YF, Chen WL, Lu YM, Li W, Liu YQ, Lai XJ, Gong YC, Liu XF, Li YG, Chen XY, Li XN, Sun HB*, Yang J*, Zhong DF*. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. European Journal of Pharmaceutical Sciences, 2019, 127: 151-16017.Liu XY, Wei Li, Zhang YF, Jiang Y, Zhao QY, Zhong DF*. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2019, 176: 11273518.Gao YX, Zhang D, Yang CY, Duan XT, Li XL, Zhong DF*. Two validated liquid chromatography-mass spectrometry methods with different pretreatment for the quantification of an anti-CD47 monoclonal antibody in rat and cynomolgus monkey serum comparing with an electrochemiluminescence method. Journal of Pharmaceutical and Biomedical Analysis, 2019, 175: 11279219.Zhu YT, Teng Z, Li W, Guo LX, Qu XJ, Wang QR, Mao SY, Chen XY, Zhong DF*. Effects of apatinib on the pharmacokinetics of nifedipine and warfarin in patients with advanced solid tumors. Drug Design, Development and Therapy, 2020, 14: 1963-197020.Chen ZD, Gao YX, Zhong DF*. Technologies to improve the sensitivity of existing chromatographic methods used for bioanalytical studies. Biomedical Chromatography, 2020, 34: e4798
jyjl:沈阳药学院，化学制药专业，本科生，获学士学位
删除或更新信息，请邮件至freekaoyan#163.com(#换成@)
